Artiva Biotherapeutics (ARTV) Cash from Investing Activities (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Cash from Investing Activities data on file, last reported at $15.3 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $15.3 million, up 53.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $68.8 million (up 157.17% YoY), and the FY2025 annual result was $63.4 million, up 152.64% from the prior year.
• Cash from Investing Activities retreated to $15.3 million in Q1 2026 per ARTV's latest filing, from $16.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $21.1 million in Q2 2025 and troughed at -$130.6 million in Q3 2024.
• A 4-year average of -$4.1 million and a median of $9.8 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities slumped 26396.55% in 2024, then surged 1760.46% in 2025.
• A 4-year view of Cash from Investing Activities shows it stood at -$2.7 million in 2023, then jumped by 63.79% to -$966000.0 in 2024, then surged by 1760.46% to $16.0 million in 2025, then decreased by 4.51% to $15.3 million in 2026.
• Business Quant data shows ARTV's Cash from Investing Activities at $15.3 million in Q1 2026, $16.0 million in Q4 2025, and $16.3 million in Q3 2025.